Shionogi & Co. (4507) on Oct. 29 raised its forecast for the year ending March 2027, lifting projected revenue to ¥720.0 billion from ¥700.0 billion and net profit attributable to owners of the parent to ¥212.5 billion from ¥210.0 billion, and increased its annual dividend forecast to ¥86 a share from ¥76.
For the April-September first half, revenue rose 64.5% from a year earlier to ¥350.4 billion, a record for the period, the company said. Operating profit climbed 55.8% to ¥115.2 billion, and net profit attributable to owners of the parent rose 44.0% to ¥119.5 billion. Royalty income totaled ¥165.4 billion, while sales by overseas subsidiaries and exports rose 210.2% to ¥95.0 billion.
| Item | Previous (May 12) | Revised |
|---|---|---|
| Revenue | ¥700.0 billion | ¥720.0 billion |
| Operating profit | ¥220.0 billion | ¥230.0 billion |
| Pretax profit | ¥220.0 billion | ¥220.5 billion |
| Net profit (parent) | ¥210.0 billion | ¥212.5 billion |
| Annual dividend | ¥76 | ¥86 |
Shionogi said first-half revenue and all profit items exceeded its forecast as growth investments made in fiscal 2025 began to contribute. Drivers included the edaravone ALS business taken over from Tanabe Pharma, sold as RADICAVA in the U.S. and Canada, expanding cefiderocol sales in the U.S. and Europe, and growth of its insomnia treatment in Japan. GSK, the parent of ViiV Healthcare, raised ViiV's forecast, and Shionogi expects higher royalty income and equity-method investment income. The company expects selling, general and administrative expenses to rise on amortization of intangible assets from its acquisition of U.S.-based IntraBio and continued U.S. investment.
The interim dividend was set at ¥40 a share, and the year-end payout forecast was raised to ¥46 from ¥38. The ¥86 annual total, up ¥15 from the previous year, would mark a 15th consecutive annual increase. Shionogi targets a dividend-on-equity (DOE) ratio of 4% or more.
Shionogi plans to file its half-year securities report on Nov. 11, 2026, and to begin paying the interim dividend on Dec. 1, 2026.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。